Question 1

How much revenue + Rx-volume + PBM-lives + payer-anchors + FDA/DEA/NABP registrations + biopharma-manufacturer-contracts + adherence-lift + $per-Rx-fee + Medicare-Part-D-plan-count + 340B-covered-entities do AI Pharmacy/PBM/Specialty/Home-Infusion startups need for Series A in 2026?

Accepted Answer

Series A gate: $3-40M net-revenue OR 100k-3M Rx-annualized OR 500k-10M PBM-lives + 3-15 payer-anchors (BCBS+Aetna+UHC+Cigna+Humana+Centene+regional Medicaid MCO) + one anchor Medicare Part D plan sponsor + NABP VAWD/DDA + state Board-of-Pharmacy multi-state licensure (>=25 states) + DEA registration if controlled + DSCSA-EPCIS+2D-DataMatrix+track-and-trace Nov-2024 stabilization / Nov-2025 full compliance + 2-8 biopharma manufacturer rebate/data/copay-assist contracts + demonstrated adherence-lift +5-15 PDC points on 3+ Star measures (SUPD/MAC/RASA) + $2-$25 per-Rx-fee blended + at least one 340B contract-pharmacy relationship or covered-entity anchor + one dated CMS Part D benefit-redesign Jan-2025 / MPPP Jan-2025 / IRA Manufacturer Discount Program readiness memo. Cautionary comps: Alto Pharmacy+Truepill+Hero+Calibrate+Noom+GoodRx Q3 2024 layoffs, WW Q1 2025 Ch-11 rumors, GLP-1 compounding sunset Feb-2025 (Hims/Ro/LifeMD/Zealthy revenue hit), Walgreens $5.2B VillageMD write-down 2024+1,200 store-closures+Sycamore Q4 2024 talks, Walmart Health closed Apr-2024, Rite Aid Ch-11 Oct-2023-emerged Aug-2024, AllianceRx-Walgreens-Prime dissolved 2022, Diplomat-Optum distressed $300M 2020, Zipdrug-Anthem wound-down 2022, Change Healthcare Feb-2024 BlackCat ransomware 100M-record HIPAA breach, Veradigm Q3 2024 restatement, Amedisys-Optum May-2023 DOJ-pending $3.3B, Kroger-Albertsons blocked FTC+9th Cir Dec-2024 $24.6B.

Question 2

What are the specific traps around the CMS Part D 2025 redesign, IRA Drug Price Negotiation (10 drugs Jan-2026, 15 more Jan-2027), the FDA GLP-1 shortage-resolved (Feb-2025 compounding sunset), the DEA telemedicine controlled-substance extensions, and Change Healthcare BlackCat (Feb-2024) that AI-pharmacy founders keep missing?

Accepted Answer

CMS Part D 2025 redesign eliminates the coverage-gap, imposes a $2,000 OOP cap Jan-2025, launches the Medicare Prescription Payment Plan (MPPP) monthly-smoothing Jan-2025, and replaces the Coverage Gap Discount Program (CGDP) with the Manufacturer Discount Program (MDP) — plan-liability shifts to sponsors above cap, so PBM/plan-sponsor tools must re-model risk-corridors and rebate-passthrough (point-of-sale DIR reform CY2024 already broke traditional back-end rebate economics). IRA Drug Price Negotiation names 10 drugs Feb-2024 (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog) effective Jan-2026 at Maximum Fair Price (MFP), with 15 more selected Feb-2025 (effective Jan-2027) and 15 more Feb-2026 (Jan-2028); Merck/BMS/Novartis/Novo/Boehringer/Astellas/Lilly/AstraZeneca lawsuits pending — DTC/PBM/specialty models must haircut branded-rebate ARR and lean on biosimilar substitution (Cordavis, Coherus, Sandoz, Teva, Amgen, Alvotech). FDA GLP-1 shortage-resolved (semaglutide Feb-2025, tirzepatide Q4 2024) sunsets 503A/503B compounding enforcement discretion — Hims/Ro/LifeMD/Zealthy/Weight Watchers revenue built on compounded semaglutide/tirzepatide has a hard regulatory expiration and requires branded-supply pivot (Novo Wegovy/Ozempic direct+NovoCare Pharmacy Mar-2024, Lilly Zepbound+LillyDirect Jan-2024) with much thinner unit economics. DEA Ryan Haight+SUPPORT Act 2018+DEA Third Temporary Extension Nov-2024 (through Dec-2025) plus DEA Special Registration for Telemedicine Proposed Feb-2025 governs controlled-substance tele-prescribing (buprenorphine, testosterone, ADHD stimulants) — models assuming permanent flexibility (Done Health, Cerebral cautionary DOJ subpoenas 2022-2024) will underwrite regulatory whiplash. Change Healthcare Feb-2024 BlackCat/ALPHV ransomware attack was the largest healthcare cyber-breach in US history (100M+ records notified Jun-2024, $22M ransom paid, $2.87B Q3 2024 UNH loss) — HIPAA Security Rule NPRM Dec-2024 (MFA + encryption-at-rest + annual pen-test + patch cadence + asset inventory mandatory) should be treated as effective now, HITRUST CSF v11.4 + SOC 2 Type II + NIST SP 800-66 must be dossier-ready for payer contracting. Miss any and Series B investors will price on regulated-model instability.

Question 3

How do the CVS-Aetna+Signify+Oak Street stack, Cigna Evernorth-Accredo, UNH OptumRx-Change $13B, Walgreens $5.2B VillageMD write-down, BrightSpring $BTSG IPO (Jan-2024), Waystar IPO (Jun-2024), and BioPlus-Elevance ($2.5B Aug-2023) reshape the 2026 pharmacy/PBM cap-table?

Accepted Answer

Seven catalysts have reset the 2026 cap-table: (1) CVS-Aetna 2018 $69B + Signify 2023 $8B + Oak Street 2023 $10.6B + Cordavis biosimilar-JV 2023 stacked payer+PBM+primary-care+specialty into one $370B-revenue entity — but Q3 2024/Q1 2025 guidance-cuts, MA V28 HCC 2024-2026 phase-in, Elevance BioPlus $2.5B Aug-2023, and Humana Q3 2024 MA-guidance-cut have compressed MLR headroom; Series B narratives that depend on payer-adoption must model 18-30 month sales cycles and value-based-care alignment (avoided-hospitalization, PDC lift, HCC recapture) not per-Rx fees. (2) Cigna Evernorth-Accredo+CuraScript+eviCore+MDLIVE consolidation makes specialty-Rx access dependent on 3 gatekeepers (Accredo, Optum Specialty, CVS Specialty); startups must ship an anchor limited-distribution-drug (LDD) manufacturer contract or accept 60-80% specialty-margin compression. (3) UNH OptumRx-Change Healthcare Oct-2022 $13B (DOJ challenge lost) + Feb-2024 BlackCat ransomware (100M-record HIPAA breach, $2.87B UNH loss) has hardened payer cyber-diligence — HITRUST + SOC 2 + NIST SP 800-66 + HIPAA Security Rule NPRM readiness is now a Series A gate not a Series C polish. (4) Walgreens VillageMD $5.2B write-down 2024 + 1,200 store-closures + Sycamore Partners Q4 2024 talks + Walmart Health closed Apr-2024 + Rite Aid Ch-11 Oct-2023-emerged Aug-2024 killed the 'retail-pharmacy-as-primary-care' thesis; investors want asset-light + PBM-agnostic + payer-diversified (Cost Plus Drugs, Capital Rx, SmithRx, Waltz Health, Rightway comp set). (5) BrightSpring $BTSG IPO Jan-2024 ($633M raised, KKR-backed PharMerica+Onco360+Amerita+ResCare stack) established the pharmacy-services roll-up IPO comp at ~1.0x revenue and ~12x adj-EBITDA — much thinner than tech multiples, so founders should not model SaaS multiples on Rx-based revenue. (6) Waystar $WAY IPO Jun-2024 ($968M raised at $3.7B market cap) revived healthcare-RCM IPO window; PBM-adjacent claims-tech (RxSense-Coupa Nov-2024, CoverMyMeds-McKesson, ePA vendors) has a clearer exit path than DTC-Rx. (7) BioPlus-Elevance Aug-2023 $2.5B + Amedisys-Optum May-2023 DOJ-pending $3.3B + PantherX Rare-CarepathRx 2023 signal the 'payer-eats-specialty-pharmacy' consolidation is not slowing — founders should model exits to Elevance CarelonRx, Humana CenterWell, UNH OptumRx, CVS Health, Cencora, McKesson, Cardinal, BrightSpring/KKR, or PE (KKR, TPG, Warburg, Bain, Advent, EQT) not IPO, and demonstrate HHS OIG AKS/Stark + Sunshine Act + EKRA + DOJ FCA + CIA audit-trail from day one to be acquirable.

AI Pharmacy, PBM, Specialty & Home Infusion Fundraising

Raising Capital for AI Pharmacy, PBM, Specialty Pharmacy & Home Infusion Startups

Frequently asked questions

Related fundraising verticals (40)